Stock Scorecard
Stock Summary for Boston Scientific Corp (BSX) - $67.96 as of 4/17/2024 8:10:54 PM EST
Total Score
9 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for BSX
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for BSX
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for BSX
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for BSX
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for BSX
Financial Details for BSX
Company Overview |
|
---|---|
Ticker | BSX |
Company Name | Boston Scientific Corp |
Country | USA |
Description | Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. |
Sector Name | LIFE SCIENCES |
Industry Name | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 4/24/2024 |
Stock Price History |
|
Last Day Price | 67.96 |
Last Day Price Updated | 4/17/2024 8:10:54 PM EST |
Last Day Volume | 6,175,049 |
Average Daily Volume | 5,781,032 |
52-Week High | 69.21 |
52-Week Low | 48.35 |
Last Price to 52 Week Low | 40.56% |
Valuation Measures |
|
Trailing PE | 63.66 |
Industry PE | 48.61 |
Sector PE | 61.99 |
5-Year Average PE | 23.63 |
Free Cash Flow Ratio | 115.19 |
Industry Free Cash Flow Ratio | 62.51 |
Sector Free Cash Flow Ratio | 30.47 |
Current Ratio Most Recent Quarter | 1.32 |
Total Cash Per Share | 0.59 |
Book Value Per Share Most Recent Quarter | 13.15 |
Price to Book Ratio | 5.19 |
Industry Price to Book Ratio | 5.21 |
Sector Price to Book Ratio | 22.08 |
Price to Sales Ratio Twelve Trailing Months | 7.03 |
Industry Price to Sales Ratio Twelve Trailing Months | 14.23 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.19 |
Share Statistics |
|
Total Shares Outstanding | 1,469,900,000 |
Market Capitalization | 99,894,404,000 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 1.94% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 285.60% |
Annual Earnings Growth | 127.94% |
Reported EPS 12 Trailing Months | 1.07 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | 2.05 |
Net Income Twelve Trailing Months | 1,591,000,000 |
Net Income Past Year | 1,591,000,000 |
Net Income Prior Year | 698,000,000 |
Quarterly Revenue Growth YOY | 14.90% |
5-Year Revenue Growth | 7.84% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 865,000,000 |
Total Cash Past Year | 865,000,000 |
Total Cash Prior Year | 930,000,000 |
Net Cash Position Most Recent Quarter | -7,767,000,000 |
Net Cash Position Past Year | -7,767,000,000 |
Long Term Debt Past Year | 8,632,000,000 |
Long Term Debt Prior Year | 8,986,000,000 |
Total Debt Most Recent Quarter | 8,632,000,000 |
Equity to Debt Ratio Past Year | 0.69 |
Equity to Debt Ratio Most Recent Quarter | 0.69 |
Total Stockholder Equity Past Year | 19,282,000,000 |
Total Stockholder Equity Prior Year | 17,573,000,000 |
Total Stockholder Equity Most Recent Quarter | 19,282,000,000 |
Options |
|
Put/Call Ratio | 1.18 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.60 |
MACD Signal | 0.65 |
20-Day Bollinger Lower Band | 54.05 |
20-Day Bollinger Middle Band | 63.43 |
20-Day Bollinger Upper Band | 72.81 |
Beta | 0.79 |
RSI | 56.95 |
50-Day SMA | 56.61 |
200-Day SMA | 45.35 |
System |
|
Modified | 4/17/2024 8:05:03 PM EST |